Markus Goebel
Directeur/Membre du Conseil chez EraGen Biosciences, Inc.
Profil
Markus Goebel is currently a Director at FoldRx.
Pharmaceuticals LLC, Sorbent Therapeutics, Inc., EraGen Biosciences, Inc., and Merganser Biotech, Inc. He previously held Director positions at Sirtris Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., Zikani Therapeutics, Inc., Locus Pharmaceuticals, Inc., LigoCyte Pharmaceuticals, Inc., Intellikine LLC, Novartis Services, Inc., eFFECTOR.
Therapeutics Operations, Inc., and ESCAPE Bio, Inc. From 2004 to 2019, he was the Managing Director at Novartis Venture Funds (USA).
Dr. Goebel holds an MBA from Henley Management College and a doctorate from Ludwig-Maximilians-Universität München.
Postes actifs de Markus Goebel
| Sociétés | Poste | Début |
|---|---|---|
EraGen Biosciences, Inc.
 EraGen Biosciences, Inc. Medical SpecialtiesHealth Technology EraGen Biosciences, Inc. is a venture-backed biotechnology company. It designs, develops, manufactures and markets molecular diagnostic testing products and software for the research and clinical testing markets. The firm in-market and pipeline products, based on its novel, patented MultiCode platform chemistry, are the next generation of nucleic acid-based testing for the early detection and monitoring of cancer, genetic and infectious diseases. The company was founded in 1994 and is headquartered in Madison WI. | Directeur/Membre du Conseil | 01/01/2004 |
Sorbent Therapeutics, Inc.
 Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Directeur/Membre du Conseil | - |
Merganser Biotech, Inc.
 Merganser Biotech, Inc. BiotechnologyHealth Technology Merganser Biotech, Inc. engages in the development of of hepcidin mimetic peptides as new medicines for the treatment of hematological and iron overload diseases. The company was founded by Brian R. MacDonald and Gene Merutka in 2011 and is headquartered in Newtown Square, PA. | Directeur/Membre du Conseil | - |
FoldRx Pharmaceuticals LLC
 FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Markus Goebel
| Sociétés | Poste | Fin |
|---|---|---|
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Private Equity Investor | 30/04/2019 |
| LigoCyte Pharmaceuticals, Inc. | Directeur/Membre du Conseil | 16/04/2014 |
ESCAPE Bio, Inc.
 ESCAPE Bio, Inc. BiotechnologyHealth Technology ESCAPE Bio, Inc. is a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | - |
Zikani Therapeutics, Inc.
 Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Directeur/Membre du Conseil | - |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | - |
Formation de Markus Goebel
| Henley Management College | Masters Business Admin |
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
EraGen Biosciences, Inc.
EraGen Biosciences, Inc. Medical SpecialtiesHealth Technology EraGen Biosciences, Inc. is a venture-backed biotechnology company. It designs, develops, manufactures and markets molecular diagnostic testing products and software for the research and clinical testing markets. The firm in-market and pipeline products, based on its novel, patented MultiCode platform chemistry, are the next generation of nucleic acid-based testing for the early detection and monitoring of cancer, genetic and infectious diseases. The company was founded in 1994 and is headquartered in Madison WI. | Health Technology |
Locus Pharmaceuticals, Inc.
 Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation. | Health Technology |
| LigoCyte Pharmaceuticals, Inc. | Health Technology |
| Novartis Services, Inc. | |
Intellikine LLC
 Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Health Technology |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Finance |
Sorbent Therapeutics, Inc.
Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Health Technology |
Merganser Biotech, Inc.
Merganser Biotech, Inc. BiotechnologyHealth Technology Merganser Biotech, Inc. engages in the development of of hepcidin mimetic peptides as new medicines for the treatment of hematological and iron overload diseases. The company was founded by Brian R. MacDonald and Gene Merutka in 2011 and is headquartered in Newtown Square, PA. | Health Technology |
Sirtris Pharmaceuticals, Inc.
 Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Health Technology |
FoldRx Pharmaceuticals LLC
FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Commercial Services |
Zikani Therapeutics, Inc.
Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Retail Trade |
ESCAPE Bio, Inc.
ESCAPE Bio, Inc. BiotechnologyHealth Technology ESCAPE Bio, Inc. is a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA. | Health Technology |